doi: 10.3389/fpsyg.2022.907637
He's back on compounded tirzepatide from his local pharmacy.
A dedicated phase 2a substudy in people with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) used MRI to measure liver fat and found that, after 24 weeks, retatrutide reduced relative liver-fat content by about 81% at the 8 mg dose and about 82% at 12 mg, versus essentially no change on placebo
Because coverage depends on your plan and diagnosis code, we review your options and provide transparent pricing, including labs and follow-up, before you start
Get Bari Connected for Weight Loss Resources & Support At ProCare Health, we aim to help bariatric community members find the support and success they deserve
Ask your pharmacy about backup vials in case of accidental damage